Back to search

Peptide record

TPDB40859

Peptide-20 P20 Anticancer Tumor-homing Peptides standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40859
Peptide-20 P20
Anticancer Tumor-homing Peptides
Cancer-related peptides
CancerPPD 2.0 Peptipedia SATPdb dbACP TumorHoPe2.0
standard
No
A 9-aa standard natural multi-activity (Anticancer and Tumor-homing Peptides) peptide sequence curated from CancerPPD 2.0, Peptipedia, SATPdb, and other sources, with an available 3D structural model.
Sequence
CSSRTMHHC
Physicochemical Analysis
C39H64N16O13S3
ANDEQGILKFPWYV
CHS
1061.22
8.30
3
0
1
+1
2.42
-0.700
0.00
Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour
125
11.78
5
Residue Composition
number
0
A
1
R
0
N
0
D
2
C
0
E
0
Q
0
G
2
H
0
I
0
L
0
K
1
M
0
F
0
P
2
S
1
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 0 H: 2 I: 0 L: 0 K: 0 M: 1 F: 0 P: 0 S: 2 T: 1 W: 0 Y: 0 V: 0
Chemical Descriptors
9
C39H64N16O13S3
1061.22
8.30
+1
2.42
-0.700
Free
L
Cyclic(C1-C9)
Free
Antitumor
Synthetic Peptide
Evidence Records 8 records
Evidence 1 Activity

Activity

at 100 µM 90% viablity
Anticancer

Target

Leukemia Cancer
HL-60
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

at 100 µM 55% viablity
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 3 Activity

Activity

at 100 µM 50% viablity
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 4 Activity

Activity

at 100 µM 50% viablity
Anticancer

Target

Skin Cancer
B16F10-Nex 2
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 5 Activity

Activity

at 100 µM 30% viablity
Anticancer

Target

Skin Cancer
A-2058
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 6 Activity

Activity

at 100 µM 55-60% viablity
Anticancer

Target

Skin Cancer
Skmel-25
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 7 Activity

Activity

at 100 µM 35-40% viablity
Anticancer

Target

Skin Cancer
Skmel-28
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 8 Activity

Activity

Tumor-homing Peptides

Target

Targeting
Skin cancer
ICAM-1 receptors

Source & Reference

TumorHoPe2.0
TumorHoPe2
Inhibition of melanoma metastasis by dual-peptide PLGA NPS
2017
Arruda D C et al. Biopolymers. 2017 Sep 108(5).

Other

Source Activity Label Source Definition
Tumor-homing Peptides
TumorHoPe2.0 experimentally validated tumor-homing peptide annotation.
B16F10-Nex2
7-8 weeks old mice, injected with B16F10-Nex2 melanoma cells.
Phage Display Library
Combined peptide C (CVNHPAFACGYGHTMYYHHYQHHL)
Additional Detail Fields 3 fields
Combined peptide C (CVNHPAFACGYGHTMYYHHYQHHL)
B16F10-Nex2
7-8 weeks old mice, injected with B16F10-Nex2 melanoma cells.